Regulatory T Cells in the tumor microenvironment and cancer progression: role and therapeutic targeting.
AffiliationCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.
MetadataShow full item record
AbstractRecent years have seen significant efforts in understanding and modulating the immune response in cancer. In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. Additionally, recent evidence indicates that Tregs comprise diverse and heterogeneous subsets; phenotypically and functionally distinct subsets of tumor-infiltrating Tregs could contribute differently to cancer prognosis and clinical outcomes. Understanding Treg biology in the setting of cancer, and specifically the tumor microenvironment, is important for designing effective cancer therapies. In this review, we critically examine the role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies. We also discuss the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting Tregs to enhance anti-tumor immune responses and clinical benefits.
CitationRegulatory T Cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. 2016, 4 (3): Vaccines (Basel)
The following license files are associated with this item:
- Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
- Authors: Sasidharan Nair V, Elkord E
- Issue date: 2018 Jan
- Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.
- Authors: Chaudhary B, Abd Al Samid M, al-Ramadi BK, Elkord E
- Issue date: 2014 Jul
- Tumor-infiltrating regulatory T cells: origins and features.
- Authors: Deng G
- Issue date: 2018
- Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.
- Authors: Wainwright DA, Dey M, Chang A, Lesniak MS
- Issue date: 2013
- Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer.
- Authors: Tsuchikawa T, Takeuchi S, Nakamura T, Shichinohe T, Hirano S
- Issue date: 2016 Nov 15